Mobile

An open, randomised, comparative, multicentre study of the immunogenicity and safety of concomitant versus separate administration of a combined measles, mumps, rubella and varicella live vaccine (Pro...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-004129-27

An open, randomised, comparative, multicentre study of the immunogenicity and safety of concomitant versus separate administration of a combined measles, mumps, rubella and varicella live vaccine (ProQuad®) and a booster dose of Infanrix® hexa in healthy children 12 to 23 months of age

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate that ProQuad® can be administered concomitantly with a booster dose of Infanrix® hexa to healthy children 12 to 23 months of age without impairing neither the antibody response rates to measles, mumps, rubella, varicella, hepatitis B and Haemophilus influenzae type b, nor the 3 pertussis antibody titres as measured at 42 days following vaccination.

Critère d'inclusion

  • The study will involve healthy children

Liens